Parkinson's disease: medical treatment of moderate to advanced disease.
Identifieur interne : 002F65 ( Main/Exploration ); précédent : 002F64; suivant : 002F66Parkinson's disease: medical treatment of moderate to advanced disease.
Auteurs : Oksana Suchowersky [Canada]Source :
- Current neurology and neuroscience reports [ 1528-4042 ] ; 2002.
English descriptors
- KwdEn :
- Amantadine (therapeutic use), Anti-Anxiety Agents (therapeutic use), Antidepressive Agents (therapeutic use), Antiparkinson Agents (therapeutic use), Antipsychotic Agents (therapeutic use), Catechol O-Methyltransferase (therapeutic use), Catechol O-Methyltransferase Inhibitors, Cholinergic Antagonists (therapeutic use), Cognition Disorders (drug therapy), Disease Progression, Dopamine Agonists (therapeutic use), Humans, Levodopa (therapeutic use), Neuroprotective Agents (pharmacology), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology).
- MESH :
- chemical , pharmacology : Neuroprotective Agents.
- chemical , therapeutic use : Amantadine, Anti-Anxiety Agents, Antidepressive Agents, Antiparkinson Agents, Antipsychotic Agents, Catechol O-Methyltransferase, Cholinergic Antagonists, Dopamine Agonists, Levodopa.
- chemical : Catechol O-Methyltransferase Inhibitors.
- complications : Parkinson Disease.
- drug therapy : Cognition Disorders, Parkinson Disease.
- physiopathology : Parkinson Disease.
- Disease Progression, Humans.
Abstract
Parkinson's disease, a common neurodegenerative disorder, results in significant morbidity 10 to 15 years after disease onset and increased mortality. Levodopa is the mainstay of therapy and provides benefit for the duration of the illness. However, within 5 years, up to 50% of individuals develop fluctuations, including dyskinesias, wearing off, and "on/off" effects. Optimal management of Parkinson's disease patients requires careful titration of medications, with use of polypharmacy, including levodopa, dopamine agonists, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergics in order to maintain good motor function and quality of life. With advancing disease, problems such as dysphagia, dysarthria, and gait and balance abnormalities occur, which are not responsive to dopaminergic medication. Due to extradopaminergic neuronal system degeneration, autonomic dysfunction can also be prominent. Recognition and management of these problems is helpful in improving quality of life in late-stage disease. In very late stages, dementia may complicate treatment, requiring discontinuation of combination therapy and use of low-dose levodopa with atypical neuroleptics.
PubMed: 12044250
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001501
- to stream PubMed, to step Curation: 001501
- to stream PubMed, to step Checkpoint: 001501
- to stream Ncbi, to step Merge: 000230
- to stream Ncbi, to step Curation: 000230
- to stream Ncbi, to step Checkpoint: 000230
- to stream Main, to step Merge: 003383
- to stream Main, to step Curation: 002F65
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease: medical treatment of moderate to advanced disease.</title><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:affiliation>Movement Disorders Program, University of Calgary, Area 3, Health Sciences Centre, 3350 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. osuchowe@ucalgary.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Program, University of Calgary, Area 3, Health Sciences Centre, 3350 Hospital Drive NW, Calgary, Alberta T2N 4N1</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12044250</idno><idno type="pmid">12044250</idno><idno type="wicri:Area/PubMed/Corpus">001501</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001501</idno><idno type="wicri:Area/PubMed/Curation">001501</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001501</idno><idno type="wicri:Area/PubMed/Checkpoint">001501</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001501</idno><idno type="wicri:Area/Ncbi/Merge">000230</idno><idno type="wicri:Area/Ncbi/Curation">000230</idno><idno type="wicri:Area/Ncbi/Checkpoint">000230</idno><idno type="wicri:doubleKey">1528-4042:2002:Suchowersky O:parkinson:s:disease</idno><idno type="wicri:Area/Main/Merge">003383</idno><idno type="wicri:Area/Main/Curation">002F65</idno><idno type="wicri:Area/Main/Exploration">002F65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Parkinson's disease: medical treatment of moderate to advanced disease.</title><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:affiliation>Movement Disorders Program, University of Calgary, Area 3, Health Sciences Centre, 3350 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada. osuchowe@ucalgary.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Movement Disorders Program, University of Calgary, Area 3, Health Sciences Centre, 3350 Hospital Drive NW, Calgary, Alberta T2N 4N1</wicri:regionArea><orgName type="university">Université de Calgary</orgName><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName></affiliation></author></analytic><series><title level="j">Current neurology and neuroscience reports</title><idno type="ISSN">1528-4042</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (therapeutic use)</term><term>Anti-Anxiety Agents (therapeutic use)</term><term>Antidepressive Agents (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Catechol O-Methyltransferase (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Cholinergic Antagonists (therapeutic use)</term><term>Cognition Disorders (drug therapy)</term><term>Disease Progression</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Neuroprotective Agents (pharmacology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Anti-Anxiety Agents</term><term>Antidepressive Agents</term><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Catechol O-Methyltransferase</term><term>Cholinergic Antagonists</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Catechol O-Methyltransferase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cognition Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease, a common neurodegenerative disorder, results in significant morbidity 10 to 15 years after disease onset and increased mortality. Levodopa is the mainstay of therapy and provides benefit for the duration of the illness. However, within 5 years, up to 50% of individuals develop fluctuations, including dyskinesias, wearing off, and "on/off" effects. Optimal management of Parkinson's disease patients requires careful titration of medications, with use of polypharmacy, including levodopa, dopamine agonists, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergics in order to maintain good motor function and quality of life. With advancing disease, problems such as dysphagia, dysarthria, and gait and balance abnormalities occur, which are not responsive to dopaminergic medication. Due to extradopaminergic neuronal system degeneration, autonomic dysfunction can also be prominent. Recognition and management of these problems is helpful in improving quality of life in late-stage disease. In very late stages, dementia may complicate treatment, requiring discontinuation of combination therapy and use of low-dose levodopa with atypical neuroleptics.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Alberta</li></region><settlement><li>Calgary</li></settlement><orgName><li>Université de Calgary</li></orgName></list><tree><country name="Canada"><region name="Alberta"><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:12044250
|texte= Parkinson's disease: medical treatment of moderate to advanced disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:12044250" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |